Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alternating CHOP-21 and DHAOx: The PTLD-2 Trial

Next Previous
Trial Profile

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alternating CHOP-21 and DHAOx: The PTLD-2 Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Granulocyte colony-stimulating factors; Oxaliplatin; Pegfilgrastim; Prednisone; Rituximab; Vincristine
  • Indications Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Acronyms PTLD-2

Most Recent Events

  • 01 Oct 2022 Results assessing efficacy and safety of subcutaneous rituximab with or without chemotherapy in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation, published in the Leukemia.
  • 14 Dec 2021 Primary endpoint has not been met. (Event free survival (EFS) of low-risk patients in the intention to treat population with following definitions for low-risk and event:), as per Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top